Embecta Corp. (NASDAQ:EMBC – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.13 and traded as low as $5.98. Embecta shares last traded at $6.09, with a volume of 715,677 shares.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded Embecta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, November 2nd. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $11.00.
Check Out Our Latest Research Report on EMBC
Embecta Stock Performance
The company has a 50-day moving average of $6.01 and a 200 day moving average of $6.13. The firm has a market cap of $345.06 million, a P/E ratio of 4.11 and a beta of 0.81.
Insider Buying and Selling at Embecta
In related news, Director Milton Mayo Morris sold 6,293 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $5.88, for a total value of $37,002.84. Following the sale, the director owned 53,828 shares of the company’s stock, valued at $316,508.64. The trade was a 10.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of EMBC. Allworth Financial LP lifted its position in Embecta by 234.1% during the third quarter. Allworth Financial LP now owns 4,707 shares of the company’s stock valued at $27,000 after purchasing an additional 3,298 shares in the last quarter. One Wealth Advisors LLC bought a new stake in shares of Embecta during the second quarter valued at approximately $33,000. Fifth Third Bancorp lifted its position in shares of Embecta by 44.2% in the third quarter. Fifth Third Bancorp now owns 7,061 shares of the company’s stock worth $40,000 after buying an additional 2,163 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Embecta by 101.5% during the 3rd quarter. GAMMA Investing LLC now owns 10,898 shares of the company’s stock valued at $62,000 after purchasing an additional 5,490 shares during the last quarter. Finally, Quadrant Capital Group LLC purchased a new position in Embecta in the 3rd quarter worth about $62,000. 93.83% of the stock is owned by institutional investors.
Embecta Company Profile
Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals. The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care. Embecta serves customers in markets around the world.
Featured Articles
- Five stocks we like better than Embecta
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
